Payment overview · 2025
General Payments
$446.56
23 reported records · 15 companies
Healthcare provider profile · identity verified
Lester Ong, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · STEPHENVILLE, TX · NPI 1255337119
Verified facts
What the public records show
CMS Open Payments records show Lester Ong, M.D. received $446.56 in general payments during 2025 across 23 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 12.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 329 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $55.24 | 12.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $54.86 | 12.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.59 | 11.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.48 | 11.3% | 3 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $32.71 | 7.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.30 | 6.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.83 | 5.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.22 | 5.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.44 | 5.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.14 | 4.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.27 | 3.9% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $15.79 | 3.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.08 | 3.4% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $14.02 | 3.1% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $13.59 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $446.56 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $55.24 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $50.48 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.82 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $38.68 | 2 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $32.71 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.30 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $25.83 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
329 | 44 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 775 | 197 |
| Levothyroxine Sodium | Levothyroxine Sodium | 628 | 142 |
| Gabapentin | Gabapentin | 599 | 125 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 582 | 108 |
| Furosemide | Furosemide | 581 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 508 | 123 |
| Lisinopril | Lisinopril | 396 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 381 | 102 |
| Losartan Potassium | Losartan Potassium | 343 | 101 |
| Glimepiride | Glimepiride | 337 | 82 |
| Potassium Chloride | Potassium Chloride | 337 | 68 |
| Alprazolam | Alprazolam | 333 | 64 |
| Prednisone | Prednisone | 331 | 193 |
| Tramadol Hcl | Tramadol Hcl | 330 | 74 |
| Eliquis | Apixaban | 329 | 44 |
| Omeprazole | Omeprazole | 303 | 86 |
| Simvastatin | Simvastatin | 274 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 270 | 78 |
| Metformin Hcl | Metformin Hcl | 268 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 256 | 63 |
| Montelukast Sodium | Montelukast Sodium | 238 | 62 |
| Sertraline Hcl | Sertraline Hcl | 218 | 46 |
| Meloxicam | Meloxicam | 210 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 210 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 184 | 38 |
| Buspirone Hcl | Buspirone Hcl | 174 | 28 |
| Trazodone Hcl | Trazodone Hcl | 172 | 38 |
| Mirtazapine | Mirtazapine | 164 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 162 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 151 | 39 |
| Carvedilol | Carvedilol | 150 | 35 |
| Clonazepam | Clonazepam | 144 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 141 | 40 |
| Divalproex Sodium | Divalproex Sodium | 140 | 19 |
| Lorazepam | Lorazepam | 140 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 139 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 137 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 133 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 33 |
| Januvia | Sitagliptin Phosphate | 125 | 16 |
| Allopurinol | Allopurinol | 118 | 29 |
| Cephalexin | Cephalexin | 114 | 89 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 20 |
| Alendronate Sodium | Alendronate Sodium | 109 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 109 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 108 | 28 |
| Ondansetron Odt | Ondansetron | 107 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 105 | 29 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 104 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 103 | 13 |
| Gemtesa | Vibegron | 102 | suppressed |
| Azithromycin | Azithromycin | 101 | 86 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 27 |
| Donepezil Hcl | Donepezil Hcl | 96 | 19 |
| Mounjaro | Tirzepatide | 92 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 90 | 64 |
| Cefuroxime | Cefuroxime Axetil | 87 | 72 |
| Celecoxib | Celecoxib | 85 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 84 | 72 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 79 | 54 |
| Levetiracetam | Levetiracetam | 77 | 11 |
| Warfarin Sodium | Warfarin Sodium | 76 | 15 |
| Atenolol | Atenolol | 75 | 22 |
| Methocarbamol | Methocarbamol | 75 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 19 |
| Pregabalin | Pregabalin | 73 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 71 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 69 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 15 |
| Aripiprazole | Aripiprazole | 67 | 17 |
| Ezetimibe | Ezetimibe | 67 | 20 |
| Ozempic | Semaglutide | 67 | 14 |
| Jardiance | Empagliflozin | 66 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 66 | 12 |
| Primidone | Primidone | 65 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 64 | suppressed |
| Memantine Hcl | Memantine Hcl | 61 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 44 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 60 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 59 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 15 |
| Sucralfate | Sucralfate | 53 | 17 |
| Spironolactone | Spironolactone | 50 | 11 |
| Nitroglycerin | Nitroglycerin | 49 | 21 |
| Diazepam | Diazepam | 48 | suppressed |
| Eszopiclone | Eszopiclone | 48 | 16 |
| Fluconazole | Fluconazole | 48 | 28 |
| Myrbetriq | Mirabegron | 48 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 12 |
| Propranolol Hcl | Propranolol Hcl | 47 | 11 |
| Bupropion Xl | Bupropion Hcl | 46 | 12 |
| Famotidine | Famotidine | 45 | 15 |
| Benztropine Mesylate | Benztropine Mesylate | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 11 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 44 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 42 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 41 | 13 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Glipizide | Glipizide | 40 | 13 |
| Temazepam | Temazepam | 40 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Finasteride | Finasteride | 39 | 14 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Olanzapine | Olanzapine | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 18 |
| Naproxen | Naproxen | 36 | suppressed |
| Carisoprodol | Carisoprodol | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 30 | 30 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Fentanyl | Fentanyl | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Nystatin | Nystatin | 21 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Ertapenem | Ertapenem Sodium | 20 | suppressed |
| Novolog | Insulin Aspart | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | 12 |
| Erythromycin | Erythromycin Base | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Np Thyroid | Thyroid,pork | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 11 |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Constulose | Lactulose | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | 11 |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Risperidone Er | Risperidone Microspheres | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 11 |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Ethosuximide | Ethosuximide | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $446.56 · 23 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, Cologuard Collection Kit, FARXIGA, Fluad, Flucelvax, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JARDIANCE, JATENZO, KRYSTEXXA, PREVNAR 20, REXULTI, TZIELD, The Cologuard Plus Collection Kit, VRAYLAR, ZENPEP, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error